COPENHAGEN, July 15 (Reuters) – Stockholm-based Neko Health, a technology firm focused on the prevention and early detection of disease, said on Wednesday it has raised $700 million in a Series C funding round ahead of the launch of its first U.S. clinic later this year.
• Funding round led by U.S. venture capital firm Lightspeed Venture Partners, and co-led by O.G. Venture Partners, Neko Health said in a statement.
• Existing investors Atomico, General Catalyst and Lakestar also participated, as did new backers such as Liberty City Ventures, Positive Sum, and Michael Dell-backed merchant bank BDT & MSD.
• Company’s clinics offer a scan which assesses skin health, including moles and marks, blood sugar levels to identify pre-diabetes risk, blood abnormalities, and risk factors linked to metabolic syndrome, stroke and heart attack.
• The 60-minute assessment, capturing millions of health data points, is priced at £299 ($400) in Britain and 2,750 Swedish crowns ($286) in Sweden.
• Neko Health was co-founded in 2018 by Hjalmar Nilsonne and Spotify boss Daniel Ek.
($1 = 0.7460 pounds)
($1 = 9.6202 Swedish crowns)
(Reporting by Louise Rasmussen, editing by Terje Solsvik)
